PL4178579T3 - 5-amino-2,3-dihydro-1,4-fthalazynodion jako środek oszczędzający glikokortykoidy - Google Patents

5-amino-2,3-dihydro-1,4-fthalazynodion jako środek oszczędzający glikokortykoidy

Info

Publication number
PL4178579T3
PL4178579T3 PL21755360.1T PL21755360T PL4178579T3 PL 4178579 T3 PL4178579 T3 PL 4178579T3 PL 21755360 T PL21755360 T PL 21755360T PL 4178579 T3 PL4178579 T3 PL 4178579T3
Authority
PL
Poland
Prior art keywords
phthalazinedione
glucocorticoid
dihydro
amino
sparing agent
Prior art date
Application number
PL21755360.1T
Other languages
English (en)
Inventor
Wolfgang Brysch
Jörg VON WEGERER
Beate Ludescher
Sara SCHUMANN
Astrid Kaiser
Petra Schulz
Original Assignee
Metriopharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metriopharm Ag filed Critical Metriopharm Ag
Publication of PL4178579T3 publication Critical patent/PL4178579T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/502Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL21755360.1T 2020-07-09 2021-07-08 5-amino-2,3-dihydro-1,4-fthalazynodion jako środek oszczędzający glikokortykoidy PL4178579T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20000248 2020-07-09
PCT/EP2021/000078 WO2022008093A1 (en) 2020-07-09 2021-07-08 Glucocorticoid-sparing agent

Publications (1)

Publication Number Publication Date
PL4178579T3 true PL4178579T3 (pl) 2025-08-11

Family

ID=71574915

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21755360.1T PL4178579T3 (pl) 2020-07-09 2021-07-08 5-amino-2,3-dihydro-1,4-fthalazynodion jako środek oszczędzający glikokortykoidy

Country Status (17)

Country Link
US (1) US20230241060A1 (pl)
EP (1) EP4178579B1 (pl)
JP (1) JP2023532972A (pl)
KR (1) KR20230038228A (pl)
CN (1) CN115916258A (pl)
AU (1) AU2021304254B9 (pl)
BR (1) BR112023000287A2 (pl)
CA (1) CA3183225A1 (pl)
ES (1) ES3029560T3 (pl)
HU (1) HUE071698T2 (pl)
IL (1) IL299528A (pl)
MX (1) MX2023000351A (pl)
NZ (1) NZ796371A (pl)
PH (1) PH12022553236A1 (pl)
PL (1) PL4178579T3 (pl)
WO (1) WO2022008093A1 (pl)
ZA (1) ZA202300309B (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11918570B2 (en) 2020-04-13 2024-03-05 The Research Foundation For The State University Of New York Method of treatment for prevention of glucocorticoid toxicity and/or enhancement of muscle regeneration via neutrophil elastase inhibition
AU2023204891A1 (en) * 2022-01-07 2024-08-08 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of congenital muscular dystrophies
WO2024117793A1 (ko) 2022-12-02 2024-06-06 주식회사 엘지에너지솔루션 배터리 팩 및 그의 제조 방법
EP4483879A1 (en) 2023-06-29 2025-01-01 MetrioPharm AG 5-amino-2,3-dihydro-1,4-phthalazinedione for the prophylaxis and treatment of thrombotic disorders
WO2025029582A2 (en) * 2023-08-01 2025-02-06 Rubicon Scientific, Llc Maintaining diethylcarbamazine in an extruded daily ration animal feed product

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2132188C1 (ru) * 1998-11-03 1999-06-27 Закрытое акционерное общество "Абидофф-Фарма" Способ лечения гипофункции щитовидной железы
US7326690B2 (en) 2002-10-30 2008-02-05 Bach Pharma, Inc. Modulation of cell fates and activities by phthalazinediones
US6953799B1 (en) 2002-10-30 2005-10-11 Bach Pharma, Inc. Modulation of cell fates and activities by diketo phthalazines
PL231885B1 (pl) 2009-01-16 2019-04-30 Abidopharma Spolka Z Ograniczona Odpowiedzialnoscia Sposób wytwarzania soli 5-amino-2,3-dihydroftalazyno-1,4-di onu z metalami alkalicznymi, ich kompozycje farmaceutyczne i ich zastosowanie
HRP20140752T1 (hr) * 2010-03-01 2014-10-24 Metriopharm Ag Kristalni oblici 5-amino-2,3-dihidroftalazin-1,4-dion natrijeve soli, farmaceutski pripravci koji ih sadrže i postupak za njihovu proizvodnju
US9464079B2 (en) 2011-03-23 2016-10-11 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
WO2016096143A1 (de) 2014-12-18 2016-06-23 Metriopharm Ag Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
EP3248602A1 (en) * 2016-05-26 2017-11-29 MetrioPharm AG Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of inflammatory and/or degenerative disorders of the tendons, ligaments of the joints, articular capsules and bursae
US11007192B2 (en) * 2016-11-07 2021-05-18 Metriopharm Ag Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of chronic progressive multiple sclerosis

Also Published As

Publication number Publication date
JP2023532972A (ja) 2023-08-01
HUE071698T2 (hu) 2025-09-28
AU2021304254B2 (en) 2025-06-26
CA3183225A1 (en) 2022-01-13
NZ796371A (en) 2026-01-30
PH12022553236A1 (en) 2024-02-12
ZA202300309B (en) 2024-05-30
EP4178579B1 (en) 2025-02-12
US20230241060A1 (en) 2023-08-03
BR112023000287A2 (pt) 2023-01-31
EP4178579C0 (en) 2025-02-12
MX2023000351A (es) 2023-05-19
EP4178579A1 (en) 2023-05-17
ES3029560T3 (en) 2025-06-24
AU2021304254B9 (en) 2025-07-10
IL299528A (en) 2023-02-01
AU2021304254A1 (en) 2023-02-16
KR20230038228A (ko) 2023-03-17
CN115916258A (zh) 2023-04-04
WO2022008093A1 (en) 2022-01-13

Similar Documents

Publication Publication Date Title
HUE071698T2 (hu) Glükokortikoid-csökkentõ szer
SG11202108552QA (en) Compounds, compositions and methods
WO2011084803A3 (en) Coloring agents and methods of use thereof
IL275193A (en) Methods for dissolving 5-amino-2,3-dihydro-1,4-phthalzindione
SG11202107690SA (en) Methods, uses & compositions
EP4125802C0 (en) 5-AMINO-2,3-DIHYDRO-1,4-PHTHALAZIN IONES FOR THE TREATMENT OF ACUTE LUNG INJURIES
EP3998265A4 (en) SELECTIVE RET INHIBITOR, METHOD FOR PREPARATION AND USE
GB202304235D0 (en) Compositions, methods and uses
EP3966223A4 (en) PEPTIDOMIMETICS, SYNTHESIS AND USES THEREOF
IL287120A (en) Compounds, preparations and methods
GB202117828D0 (en) New formulations
GB2613256B (en) Compositions, and methods and uses relating thereto
IN2012DN05142A (pl)
EP4319823A4 (en) Porphyrin-hydroporphyrin compounds, compositions containing them and methods of using them
GB202401977D0 (en) Compositions, methods and uses
GB2609091B (en) Compositions, and methods and uses relating thereto
IL320161A (en) Compounds, compositions and methods
GB202305630D0 (en) Compositions, methods and uses
GB202107977D0 (en) Method, composition and use
WO2011006097A3 (en) Methods For Treating Toxicity
GB202302074D0 (en) Agents, methods and uses thereof
GB202415328D0 (en) Compositions, methods and uses
GB202405929D0 (en) Compositions, uses and methods
GB202311075D0 (en) Compositions, methods and uses
GB202207859D0 (en) Compositions, methods and uses